Fennec Pharmaceuticals

Fennec Pharmaceuticals is dedicated to improving the lives of children with cancer who experience hearing loss as a result of chemotherapy. The company focuses on reducing the risk of ototoxicity in pediatric patients receiving cisplatin-based chemotherapy. PEDMARK® is the first and only FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic solid tumors, receiving FDA approval in September 2022. PEDMARQSI® received European Commission Marketing Authorization in June 2023 and U.K. approval in October 2023. PEDMARK® has received Orphan Drug Exclusivity in the U.S. for seven years of market protection, while PEDMARQSI® has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Fennec Pharmaceuticals entered into an exclusive licensing agreement with Norgine to commercialize PEDMARQSI® in Europe, Australia, and New Zealand, receiving approximately €40 million upfront and up to €210 million in additional commercial and regulatory milestone payments. The company reported first quarter 2024 total net revenues of $25.4 million, including $18.0 million in licensing revenue from the Norgine transaction, and has approximately $51 million in cash, cash equivalents, and investment securities as of the first quarter of 2024. Fennec Pharmaceuticals participated in eleven regional oncology conferences and seven key scientific meetings in the first quarter of 2024. The company recorded net product sales of $7.4 million and $18.0 million in licensing revenue for the first quarter of 2024. PEDMARK® is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. The company has a Compassionate Use Program in Turkey for newly diagnosed hepatoblastoma, which started on October 21, 2019. Fennec Pharmaceuticals supports clinical trials such as ACNS2031 for newly diagnosed average risk medulloblastoma and STS J-01 for newly diagnosed solid tumors. The company is headquartered at 68 TW Alexander Drive, Research Triangle Park, NC 27709. Fennec Pharmaceuticals is committed to sparing children from the ototoxic effects of cisplatin-based chemotherapy, which can significantly impair cognitive performance and the development of social and language skills.